The $40 million expansion project, scheduled to be completed in August 2009, will more than triple its size to provide researchers with cutting-edge facilities and create 50 high-end jobs.
Cambridge Major is one of the premier research and development firms in the United States, supplying advanced scientific services to biotech and pharmaceutical producers around the world.
The facility will house initially six manufacturing suites with reactors up to a 2,000-gallon scale with complete isolation and containment. In addition, the facility will house several vessels for hydrogenation and cryogenic reactions, giving the site maximum flexibility and utility. Cambridge Major is one of the premier research and development firms in the United States, supplying advanced scientific services to biotech and pharmaceutical producers around the world.
The facility has been designed to accommodate additional manufacturing suites up to a 4,000-gallon scale, and these will be built out as the needs arise.
Cambridge Major opened in a new state-of-the-art API development and small-volume manufacturing site in Germantown in 2004, and this facility is currently approaching the maximum of its operating capacity. As such the company requires more capacity for later stage clinical and commercial API’s.
Altogether the company has three API development sites in the United States and Europe that will feed large scale manufacturing opportunities into the new site.
The company is expected to complete more than 400 developmental projects in 2008.
“It is vitally important for us to extend our service offerings as we have numerous projects in Phase III clinical trials, and our desire is to retain the technology and customers for the initial several years of commercial manufacturing,” said Michael Major, president and CEO of the company. “Since there will be no tech transfers or re-validations of processes and suppliers, delivery of API should be guaranteed along with significant time and cost savings. This will also free additional capacity in our existing developmental plants, in particular where cryogenic reactions and hydrogenations are part of the process.”
As part of Cambridge Major’s growth strategy announced in 2007, it is investing internally and through acquisition to continue to drive the 30 percent annual growth rate the company has experienced since its inception in 1999.
The state of Wisconsin has set a goal of capturing 10 percent of the market for biotechnology and stem cell research by 2015. To reach these goals, the state launched a $750 million initiative to develop stem cell research and biotechnology in Wisconsin.
Earlier this year, ground was broken on a $150 million Institutes for Discovery, a public-private partnership to advance biological and medical research and the development of life-saving technologies.
For MORE NEWS BRIEFS, click here.
Means the article is accessible only to our magazine subscribers.
